ST8SIA6-AS1, a novel lncRNA star in liver cancerdoi:10.3389/fcell.2024.1435664Cheng QiuHaoran FanSiyu TaoZiqing DengHongliang LuoFangteng LiuFrontiers in Cell & Developmental Biology
ST8SIA6-AS1 accelerated cell growth, invasion, and migration and suppressed apoptosis in LIHC. Notably, ST8SIA6-AS1 inhibited HMGA1 expression by sponging miR-142-3p in LIHC cells. In conclusion, sponging of miR-142-3p by ST8SIA6-AS1 accelerated the growth of cells while preventing cell ...
Moreover, ST8SIA6-AS1 targeted miR-338-3p to modulate the expression of NONO in HCC cells. Conclusions: ST8SIA6-AS1 enhances the progression of HCC via miR-338-3p/NONO axis in vitro.doi:10.1016/j.dld.2021.02.012Jinghua KuaiLijie Zheng...
骨肉瘤增殖迁移目的 探讨ST8SIA6-AS1对骨肉瘤细胞增殖和转移的影响及其分子机制.方法 选取37例骨肉瘤患者的瘤组织及瘤旁组织,采用实时荧光定量聚合酶链反应(qRT-PCR)检测ST8SIA6-AS1,miR-223-3p的表达水平.将骨肉瘤细胞U2OS分为 si-ST8SIA6-AS1 组,si-NC 组,miR-223-3p mimic 组,miR-NC 组,s... ...
In terms of mechanism, ST8SIA6-AS1 regulated melanoma-associated antigen (MAGE)-A3 (MAGEA3) and DDB1-and Cul4-associated factor 4-like 2 (DCAF4L2) expression, and rescue experiments verified that ST8SIA6-AS1 played a protumorigenic role in HCC via the regulation of MAGEA3 and DCAF4L2...
ST8SIA6-AS1HDAC11miR-4656Hepatocellular carcinoma cell linesCell proliferationApoptosisPrimer sequencesdoi:10.1186/s12935-020-01325-5Qiang FeiFeihong SongXinwei JiangHan HongMinhui XuCancer Cell International
具体为一种长链非编码RNA ST8SIA6AS1作为垂体瘤分子标志物的应用,所述应用包括长链非编码RNA ST8SIA6AS1的检测试剂在制备垂体瘤诊断与预后检测试剂盒中的应用;或长链非编码RNA ST8SIA6AS1的抑制剂在制备治疗垂体瘤的药物中的应用;其中,长链非编码RNA ST8SIA6AS1的核苷酸序列如SEQ ID NO.1所示,本发明为垂体瘤...
以及一种能敲降上述长链非编码RNA的表达水平的物质在制备治疗肿瘤的药物中的用途;以及一种治疗肿瘤的药物,药物中含有能敲降上述长链非编码RNA的表达水平的物质.本发明中的ST8SIA6AS1作为新的肿瘤分子标志物,其高表达可预示肿瘤的不良预后;作为肿瘤治疗靶点,两条反义锁核酸均可特异敲降ST8SIA6AS1的表达水平,高效,...
EXPERIMENTAL medicineThe article focuses on the retraction of a study about lncRNA ST8SIA6AS1's role in liver cancer proliferation and invasion due to concerns over the use of duplicated cell migration assay data from previously published works....
以及一种能敲降上述长链非编码RNA的表达水平的物质在制备治疗肿瘤的药物中的用途;以及一种治疗肿瘤的药物,药物中含有能敲降上述长链非编码RNA的表达水平的物质.本发明中的ST8SIA6AS1作为新的肿瘤分子标志物,其高表达可预示肿瘤的不良预后;作为肿瘤治疗靶点,两条反义锁核酸均可特异敲降ST8SIA6AS1的表达水平,高效,...